SIGRID FORMANTES: Open Payments
NPI 1881840023 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,073 in 150 payments from 16 companies in 2025. Trend: 2023 $1,335 · 2024 $1,377 · 2025 $3,073
Food & beverage: $3,073
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $464 |
| ABBVIE INC. | 22 | $463 |
| Neurocrine BioSciences, Inc. | 16 | $409 |
| Teva Pharmaceuticals USA, Inc. | 17 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $285 |
| Vanda Pharmaceuticals Inc. | 11 | $223 |
| E.R. Squibb & Sons, L.L.C. | 11 | $191 |
| Alkermes, Inc. | 8 | $161 |
| Bausch Health US, LLC | 6 | $139 |
| Janssen Pharmaceuticals, Inc | 7 | $119 |
Products named: VRAYLAR, INGREZZA, REXULTI, AUSTEDO XR, CAPLYTA, FANAPT, COBENFY, ARISTADA.
Industry payments across CA — which companies pay providers there.
